Bristol Myers, Lilly venture arm back new startup out of Dana-Farber


A blood plasma-testing company born out at the Dana-Farber Cancer Institute is launching with $57 million and a plan to speed up precision medicine.

Previous The 'double shift': Supporting women in the life science industry who balance work, family
Next The landscape of tipping in Birmingham: When, why and how much?